scholarly journals Full-Thickness Retinochoroidal Incision in the Management of Central Retinal Vein Occlusion

2015 ◽  
Vol 2015 ◽  
pp. 1-7
Author(s):  
San-Ni Chen ◽  
Ya-Chi Huang
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vitreous Hemorrhage ◽  
Retinal Hemorrhage ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Full Thickness ◽  
Ischemic Group ◽  
Vein Occlusion ◽  
Central Retinal Vein

Purpose.To evaluate the clinical outcomes in patients with central retinal vein occlusion (CRVO) treated with full-thickness retinochoroidal incisions and to compare whether there is difference in treatment response in ischemic and nonischemic CRVO.Methods.Retrospective study of patients of CRVO receiving full-thickness retinochoroidal incisions in Changhua Christian Hospital. Fluorescein angiography (FA), slit-lamp biomicroscopy, indirect funduscopy, best corrected visual acuity, and central macular thickness (CMT) measured by optical coherence tomography were performed pre- and postoperatively. Patients were divided into an ischemic and nonischemic group according to the findings of FA. Patients were followed up for at least 1 year.Results.Twenty-eight eyes (14 ischemic and 14 nonischemic CRVO) were included. Functional retinochoroidal venous anastomosis (RCVA) was achieved in 48 of the 65 retinochoroidal incisions (73.8%). Central macular thickness (CMT) and retinal hemorrhage decreased significantly after the surgery. Significant visual gain was observed postoperatively in the nonischemic group, but not in the ischemic group. Postoperative complications included vitreous hemorrhage (17.8%), neovascular glaucoma (7.1%), and preretinal fibrovasular membrane (10.7%), all of which were in the ischemic group.Conclusions.RCVA formation induced by retinochoroidal incisions could improve venous flow, and decrease CMT and retinal hemorrhage. However, only eyes with nonischemic CRVO showed visual improvement.

scholarly journals CHARACTERISTIC AND TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION IN CIPTO MANGUNKUSUMO HOSPITAL, INDONESIA

2020 ◽  
Vol 4 (7) ◽  
Author(s):  
Nova Diana ◽  
Andi Arus Victor
Keyword(s):  
Diabetes Mellitus ◽  
Visual Acuity ◽  
Triamcinolone Acetonide ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Laser Photocoagulation ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Vein Occlusion ◽  
Central Retinal Vein

Background: To evaluate the characteristics and treatment of central retinal vein occlusion (CRVO) in Vitreoretinal Division in Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Methods: A retrospective descriptive study was conducted in 79 subjects (80 eyes) with CRVO. Study groups were divided into 4 groups; laser photocoagulation, intravitreal bevacizumab (IVB), combination of IVB and laser photocoagulation (IVB/laser), also intravitreal triamcinolone acetonide (IVTA) group. Visual acuity evaluation and central macular thickness (CMT) measurement were performed for 6 months therapy. Results: This study found 43 eyes with ischemic CRVO (53.25%) and 37 eyes observed with non-ischemic type (46.25%). The common risk factors of CRVO in this study were hypertension (65.8%), diabetes mellitus (30.4%) and dyslipidemia (22.8%), while the most frequent complication was macular edema (87.5%). The improvement in central macular thickness was found in most of the patients with both CRVO types in all treatment groups. Meanwhile, the improvement of visual acuity was mostly found in patients with ischemic CRVO in IVB with/without laser group. Conclusion: Hypertension, diabetes mellitus and dyslipidemia patients should be aware of CRVO incidence. IVB with/without laser may be suggested as the treatment of choice for ischemic and non-ischemic CRVO patients in our hospital. Keyword: anti-vascular endothelial growth factor, bevacizumab, central retinal vein occlusion, intravitreal injection of triamcinolone acetonide, laser photocoagulation

scholarly journals Disease-modifying effects of ranibizumab for central retinal vein occlusion

2021 ◽  
Author(s):  
Jason M. Huang ◽  
Rahul N. Khurana ◽  
Avanti Ghanekar ◽  
Pin-wen Wang ◽  
Bann-Mo Day ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Low Frequency ◽  
Underlying Disease ◽  
Retinal Hemorrhage ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Disease Modifying ◽  
Future Work ◽  
Central Retinal Vein

Abstract Purpose To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central optical coherence tomography outcomes. Methods A post hoc analysis of a double-masked, multicenter, randomized clinical trial was performed. A total of 392 patients with macular edema after CRVO were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham injections. Central reading center-read data were reviewed to explore potential anatomic endpoints altered by therapy. Results At 6 months, there was a reduction in the ranibizumab groups compared with sham groups with respect to total area of retinal hemorrhage (median change from baseline in disc areas: − 1.17 [sham], − 2.37 [ranibizumab 0.3 mg], − 1.64 [ranibizumab 0.5 mg]), development of disc neovascularization (prevalence: 3% [sham], 0% [ranibizumab 0.3 mg], 0% [ranibizumab 0.5 mg]), and presence of papillary swelling (prevalence: 22.9% [sham], 8.0% [ranibizumab 0.3 mg], 8.3% [ranibizumab 0.5 mg], p < 0.01). There was no difference between groups in collateral vessel formation. Analysis of vitreous and preretinal hemorrhage could not be performed due to low frequency of events in both treated and sham groups. Conclusions Ranibizumab for CRVO resulted in beneficial disease-modifying effects through a reduction in retinal hemorrhage, neovascularization, and papillary swelling. These findings may form the basis for future work in the development of a treatment response or severity scale for eyes with CRVO.

scholarly journals Macular profile of eyes developing macular holes in cases of central retinal vein occlusion treated with Bevacizumab

2020 ◽  
Vol 9 (1) ◽  
pp. 13-19
Author(s):  
Anadi Khatri ◽  
Pratap Karki ◽  
Sagun Narayan Joshi ◽  
Bal Kumar Khatri ◽  
Muna Kharel ◽  
...  
Keyword(s):  
Macular Edema ◽  
Macular Hole ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vascular Endothelial ◽  
Full Thickness ◽  
Vein Occlusion ◽  
Macular Holes ◽  
Full Thickness Macular Hole ◽  
Central Retinal Vein

Background: Anti-vascular endothelial growth factors are commonly used for treatment for central retinal vein occlusion. There have been numerous reports regarding both the benefits and disadvantages of its use. Recently, a rather surprising complication- development of macular holes have started emerging. Objectives: The purpose of this study was to evaluate if the patient's profile, baseline optical coherence tomography parameters, status of the vitreous and subsequent response pose a risk for macular hole formation in cases of central retinal vein occlusion central retinal vein occlusion following treatment with bevacizumab.  Methodology: This prospective exploratory analytical study was conducted at a tertiary eye care center of Nepal and evaluated 97 eyes with central retinal vein occlusion undergoing treatment with bevacizumab. Results: Full Thickness Macular Hole  developed in eight (8.24%) of the central retinal vein occlusion eyes treated with bevacizumab. Elderly age and eyes with cystoid edema at baseline were found to have greater risk of developing macular hole following treatment (OR: 8.97 , p<0.05). Twelve eyes (12.3%) of the eyes treated developed vitreoretinal interface anomalies and were the result of dramatic decrease in central macular thickness . All of them had cystoid macular edema at baseline. Five of them (42%) developed full thickness macular hole. Conclusion: Anti-vascular endothelial growth factor agents have been widely accepted as the first line of choice for treatment of macular edema secondary to central retinal vein occlusion. Cystoid macular edema, eyes of the elderly and those showing dramatic decrease in central macular thickness with the development of anomalous vitreoretinal interface are potential risk factors for full thickness macular hole.

scholarly journals ROLE OF BEVACIZUMAB FOR PREVENTION OF NEOVASCULAR GLAUCOMA IN ACUTE RETINAL VEIN OCCLUSION

2018 ◽  
Vol 9 (1) ◽  
pp. 64-67
Author(s):  
Bassam Mubarik ◽  
Adeen Akram
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Neovascular Glaucoma ◽  
Ischemic Group ◽  
Vein Occlusion ◽  
Group 2 ◽  
Central Retinal Vein

ABSTRACT:There is a possibility of developing neovascular glaucoma in ischemic type of retinal vein occlusion. Purpose of the study is to determine the role of anti VEGF agent bevacizumab for prevention of neovascular glaucoma in ischemic type of retinal vein occlusion.METHOD: It was a retrospective study of 34 cases with unilateral central retinal vein occlusion. All of them were treated with intra vitreous Bevacizumab for management of associated macular edema. Primary outcome was to study development of neovascular glaucoma in these cases.RESULTS: Thirty four cases were selected with retinal vein occlusion. Seventeen cases were of non ischemic type and remaining 17 were of ischemic type vein occlusion. During a follow up period of two years non ischemic group was given on average 8 bevacizumab injection. Only one of these non ischemic eyes developed neo vessels of optic disc but neo vascular glaucoma did not develop. In case of ischemic group during follow up period of two years a mean of 6 bevacizumab injections were given. In this ischemic group 2 cases developed iris neovesseles and 3 cases developed retinal neovesseles. Out of these, three eyes progressed to neovascular glaucoma.CONCLUSION: Bevacizumab treatment of macular edema for ischemic central retinal vein occlusion does not prevent neovascular glaucoma.

Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

1994 ◽  
Vol 72 (01) ◽  
pp. 039-043 ◽  
Author(s):  
Francesco Bandello ◽  
Silvana Vigano’ D’Angelo ◽  
Mariella Parlavecchia ◽  
Alessandra Tavola ◽  
Patrizia Della Valle ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Specific Treatment ◽  
Fibrin Deposition ◽  
Heparin Cofactor Ii ◽  
Lipoprotein A ◽  
Vein Occlusion ◽  
Acute Event ◽  
D Dimer ◽  
Central Retinal Vein

SummaryA series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

Sign in / Sign up

Export Citation Format

Share Document